Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.58 |
| ▸ | DRD4 | P21917 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
| ▸ | WDR5 | P61964 | 1/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.51 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | PPARD | Q03181 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6846964 | 0.94 | DRD2 (0.57) | DRD2DRD4LMNAMAPK1HTT | |
| SCHEMBL8035908 | 0.93 | HRH3 (0.57) | DRD2DRD4LMNAMAPK1HTT | |
| SCHEMBL3167075 | 0.90 | LMNA (0.59) | DRD2DRD4LMNAMAPK1HTT | |
| SCHEMBL9808215 | 0.86 | LMNA (0.67) | DRD2DRD4LMNAMAPK1HTT | |
| SCHEMBL1685432 | 0.84 | DRD2 (0.62) | DRD2DRD4LMNAMAPK1HTT | |
| SCHEMBL9774806 | 0.82 | DRD2 (0.60) | DRD2DRD4LMNAMAPK1HTT | |
| SCHEMBL10458289 | 0.82 | LMNA (0.59) | DRD2DRD4LMNAMAPK1HTT | |
| SCHEMBL21742155 | 0.82 | WDR5 (0.59) | DRD2DRD4LMNAMAPK1HTT | |
| SCHEMBL6852942 | 0.81 | DRD2 (0.58) | DRD2DRD4LMNAMAPK1HTT | |
| SCHEMBL5825855 | 0.81 | KMT2A (0.60) | DRD2DRD4LMNAMAPK1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015155306-A1 | NEW TRPA1 ANTAGONISTS | ALMIRALL, S.A. (ES) | 2015-10-15 | — | — | WO | disclosed |
| EP-1444300-A1 | METHOD FOR SOLIDIFICATION OF A LIQUID PAINT COMPONENT | DSM IP Assets B.V. (NL) | 2004-08-11 | — | — | EP | disclosed |
| US-6756384-B2 | TREATMENT OF DISEASES AND DISORDERS RELATED TO THE HISTAMINE H3 RECEPTOR. | NOVO NORDISK A/S (DK) | 2004-06-29 | — | — | US | disclosed |
| US-20030181446-A1 | Novel N-acylated heterocycles | RECORDATI S.A. | 2003-09-25 | — | — | US | disclosed |
| US-20030162777-A1 | Novel N-acylated heterocycles | RECORDATI S.A. | 2003-08-28 | — | — | US | disclosed |
| US-20030135056-A1 | Imidazole compounds | HIGH POINT PHARMACEUTICALS, LLC | 2003-07-17 | — | — | US | disclosed |
| WO-2003025073-A1 | METHOD FOR SOLIDIFICATION OF A LIQUID PAINT COMPONENT | DSM IP ASSETS B.V. (NL) | 2003-03-27 | — | — | WO | disclosed |
| EP-1295915-A1 | Method for solidification of a liquid paint component | DSM N.V. (NL) | 2003-03-26 | — | — | EP | disclosed |
| EP-1268484-A1 | CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS | NOVO NORDISK A/S (DK) | 2003-01-02 | — | — | EP | disclosed |
| US-6437147-B1 | FOR THERAPY OF DISEASES OF CENTRAL NERVOUS SYSTEM, PERIPHERAL NERVOUS SYSTEM, CARDIOVASCULAR SYSTEM, PULMONARY SYSTEM, GASTROINTESTINAL SYSTEM AND ENDOCRINOLOGICAL SYSTEM | NOVO NORDISK (DK) | 2002-08-20 | — | — | US | disclosed |
| US-20020058659-A1 | Imidazole compounds | HIGH POINT PHARMACEUTICALS, LLC | 2002-05-16 | — | — | US | disclosed |
| WO-2001068652-A1 | CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS | NOVO NORDISK A/S (DK) | 2001-09-20 | — | — | WO | disclosed |
| EP-0183147-A2 | Beta-substituted aminophenethylazol derivatives | NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) | 1986-06-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162777-A1 | Novel N-acylated heterocycles | HTR1A, HTR1D, HTR1E | DRD2 163/4885DRD4 494/4885LMNA 2397/4885 |
| US-20030135056-A1 | Imidazole compounds | HRH3, HRH4, HRH2 | DRD2 668/4885DRD4 1390/4885LMNA 4098/4885 |
| US-20020058659-A1 | Imidazole compounds | HRH3, HRH4, HRH2 | DRD2 668/4885DRD4 1390/4885LMNA 4098/4885 |
| US-20030181446-A1 | Novel N-acylated heterocycles | HTR1A, HTR1E, HTR2C | DRD2 85/4885DRD4 157/4885LMNA 921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.